IFRX (InflaRx NV) Total Liabilities: $13.87 Mil (As of Mar. 2026)


IFRX InflaRx NV IFRX
31 GF Score
Price $2.24
! 5 Warning Signs
View Full Analysis

What is InflaRx NV Total Liabilities?

InflaRx NV IFRX -3.03% 31 Total Liabilities is $13.87 Mil as of Mar. 2026. GuruFocus rates IFRX with a GF Score™ of 31/100. The stock has 5 warning signs investors should review.

InflaRx NV's Total Liabilities for the quarter that ended in Mar. 2026 was $13.87 Mil.

InflaRx NV's quarterly Total Liabilities declined from Sep. 2025 ($23.23 Mil) to Dec. 2025 ($16.00 Mil) and declined from Dec. 2025 ($16.00 Mil) to Mar. 2026 ($13.87 Mil).

InflaRx NV's annual Total Liabilities declined from Dec. 2023 ($19.22 Mil) to Dec. 2024 ($15.29 Mil) but then increased from Dec. 2024 ($15.29 Mil) to Dec. 2025 ($16.00 Mil).

InflaRx NV Total Liabilities Historical Data

* Premium members only.

The historical data trend for InflaRx NV's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InflaRx NV Total Liabilities Chart

InflaRx NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.44 14.88 19.22 15.29 16.00

InflaRx NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.88 18.91 23.23 16.00 13.87
IFRX
31GF Score
InflaRx NV IFRX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InflaRx NV Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

InflaRx NV's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=15.201+(0.751+0.042999999999999
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=16.00

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=64.656-48.662
=15.99

InflaRx NV's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=13.169+(0.661+0.042999999999999
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=13.87

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=56.52-42.647
=13.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $13.87 Mil mean?
InflaRx NV (IFRX) has a Total Liabilities of $13.87 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for InflaRx NV and its competitors.
Is InflaRx NV's Total Liabilities too high?
InflaRx NV's current Total Liabilities is $13.87 Mil. Overall, InflaRx NV has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does InflaRx NV's Total Liabilities compare to BCYC and ELDN?
InflaRx NV's Total Liabilities of $13.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for InflaRx NV and its competitors. InflaRx NV's current Total Liabilities is $13.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InflaRx NV stock overvalued right now?
InflaRx NV (IFRX) has a current Total Liabilities of $13.87 Mil. The current Total Liabilities is $13.87 Mil. InflaRx NV's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For InflaRx NV (IFRX), the current Total Liabilities is $13.87 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

InflaRx NV Business Description

Other Exchanges IF0:Germany
Address Winzerlaer Strasse 2, Jena, DEU, 07745
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
31GF Score

Get the complete analysis for IFRX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.24
Price